News
Blueprint and Roche take on Lilly as FDA approves RET-target...
Cancer drugs firm Blueprint Medicines has gained a second US approval, with its Gavreto (pralsetinib) daily pill that targets non-small cell lung cancer with RET fusion mutations.<
